Therapy targeted to the tumour vasculature has become an attractive area of cancer therapeutics. There is nothing new in the concept of strangulating the blood supply of malignant cells that require abundant nutrition for their rapid turnover, but progress with this strategy has been hindered by scarcity of agents and difficulty in establishing experimental models. Over the past decade knowledge of vascular physiology has increased and new antiangiogenic agents have become available. The attraction of this strategy has grown as we have acknowledged the slow progress of research in cytotoxic therapy.
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Antiangiogenic Agents in Cancer Therapy covers in three equal sections the topics of tumour vasculature development and control, antiangiogenic agents, and in-vivo studies and clinical trials. The first section can be a little taxing for the clinician who is not directly involved in tumour vascular targeting, but selective reading of chapters about FGFs (fibroblast growth factors) and VEGFs (vascular endothelial growth factors) will provide an excellent background to the basic physiology of these substances which are important in the control of vasculature and are targets for agents that have been and continue to be developed for clinical studies. The chapters are clearly laid out and well referenced, but sparsely illustrated.
The second section provides a detailed account of antiangiogenic agents, and should appeal to both scientists and clinicians. Of particular interest to clinicians is a chapter on cartilage as a source of natural inhibitors of angiogenesis. Many oncologists have patients who consume large amounts of shark cartilage; this may be a desperate measure, but the plates illustrating the inhibition of the formation of vitelline blood vessels in the chick embryo are quite impressive. The re-emergence of thalidomide as an antiangiogenic agent is receiving much attention and several related compounds are undergoing investigation in preclinical models. No such book would be complete without a description of angiostatin and endostatin, two molecules that have been given considerable publicity in the medical and lay press over the last few years; however, the chapter is not easy to follow.
The final section is the one probably of greatest interest to the clinical scientists. I was particularly impressed by the first chapter (written by the editor) describing the potentiation of cytotoxic agents by antiangiogenic agents. Successful cancer therapy will probably depend on use of more than one approach and clinical studies of the interaction of cytotoxic agents such as cyclophosphamide, platinum derivatives and paclitaxel will soon be underway. However, biological measurement of their activity is probably the greatest obstacle delaying their entry into the clinic. I had hoped for some enlightenment from the chapter dedicated to endpoints for determination of efficacy of these agents in clinical trials. Although comprehensive this chapter gave more emphasis to the problems of measurement than to the solutions. There was little information about clinical trials with antiangiogenic compounds probably a reflection of the novelty of this field of research. A description of clinical studies with agents that have been available longest was most complete-retinoids, interferons, matrix metalloproteinase inhibitors (surprisingly brief) and pentosan sulphate. TNP-470, a synthetic analogue of fumagillin, a compound secreted by the fungus Aspergillusfumigatusfresenius, was for me one of the most interesting of the new agents presented in this book. Clinical benefit, chiefly disease stabilization, was seen in several patients in the phase I studies.
The book, with its comprehensive review of antiangiogenic agents, will appeal most to scientists and clinicians directly involved in tumour vasculature research. It is also recommended to any researcher, clinical or scientific, who is about to embark on studies in this very important area. Collins and Kennedy relate the failure to prevent such infections to: lack of instruction in safe procedures for handling infected material; the removal of trained and experienced workers from the laboratory to managerial posts elsewhere; the emergence of new and resurgence of old diseases which have caught some people unawares; poorly designed and ill equipped laboratories; lack of protection of workers; and an inadequate system of inspection of premises where pathogens are handled. Their book starts with a discussion of what is meant by laboratoryacquired infections, as distinct from laboratory-associated infection. Considerable detail is recorded with respect to every organism that has ever caused such infection, with a summary of publications relating to individual cases. The authors go on to describe exposure, sources and routes of
